Mechanisms of normal and tumor-derived angiogenesis

被引:568
作者
Papetti, M [1 ]
Herman, IM [1 ]
机构
[1] Tufts Univ, Sch Med, Dept Cellular & Mol Physiol, Boston, MA 02111 USA
来源
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY | 2002年 / 282卷 / 05期
关键词
blood vessel; growth; cancer; endothelium; pericyte;
D O I
10.1152/ajpcell.00389.2001
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Often those diseases most evasive to therapeutic intervention usurp the human body's own cellular machinery or deregulate normal physiological processes for propagation. Tumor-induced angiogenesis is a pathological condition that results from aberrant deployment of normal angiogenesis, an essential process in which the vascular tree is remodeled by the growth of new capillaries from preexisting vessels. Normal angiogenesis ensures that developing or healing tissues receive an adequate supply of nutrients. Within the confines of a tumor, the availability of nutrients is limited by competition among actively proliferating cells, and diffusion of metabolites is impeded by high interstitial pressure (Jain RK. Cancer Res 47: 3039-3051, 1987). As a result, tumor cells induce the formation of a new blood supply from the preexisting vasculature, and this affords tumor cells the ability to survive and propagate in a hostile environment. Because both normal and tumor-induced neovascularization fulfill the essential role of satisfying the metabolic demands of a tissue, the mechanisms by which cancer cells stimulate pathological neovascularization mimic those utilized by normal cells to foster physiological angiogenesis. This review investigates mechanisms of tumor-induced angiogenesis. The strategies used by cancer cells to develop their own blood supply are discussed in relation to those employed by normal cells during physiological angiogenesis. With an understanding of blood vessel growth in both normal and abnormal settings, we are better suited to design effective therapeutics for cancer.
引用
收藏
页码:C947 / C970
页数:24
相关论文
共 269 条
  • [71] The ephrins and Eph receptors in neural development
    Flanagan, JG
    Vanderhaeghen, P
    [J]. ANNUAL REVIEW OF NEUROSCIENCE, 1998, 21 : 309 - 345
  • [72] ISOLATION OF A TUMOR FACTOR RESPONSIBLE FOR ANGIOGENESIS
    FOLKMAN, J
    MERLER, E
    ABERNATHY, C
    WILLIAMS, G
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1971, 133 (02) : 275 - +
  • [73] ANGIOGENESIS INHIBITION AND TUMOR-REGRESSION CAUSED BY HEPARIN OR A HEPARIN FRAGMENT IN THE PRESENCE OF CORTISONE
    FOLKMAN, J
    LANGER, R
    LINHARDT, RJ
    HAUDENSCHILD, C
    TAYLOR, S
    [J]. SCIENCE, 1983, 221 (4612) : 719 - 725
  • [74] ANGIOGENIC FACTORS
    FOLKMAN, J
    KLAGSBRUN, M
    [J]. SCIENCE, 1987, 235 (4787) : 442 - 447
  • [75] ANGIOGENESIS IN CANCER, VASCULAR, RHEUMATOID AND OTHER DISEASE
    FOLKMAN, J
    [J]. NATURE MEDICINE, 1995, 1 (01) : 27 - 31
  • [76] FOLKMAN J, 1988, AM J PATHOL, V130, P393
  • [77] WHAT IS THE EVIDENCE THAT TUMORS ARE ANGIOGENESIS DEPENDENT
    FOLKMAN, J
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (01): : 4 - 6
  • [78] ROLE OF THE FLT-1 RECEPTOR TYROSINE KINASE IN REGULATING THE ASSEMBLY OF VASCULAR ENDOTHELIUM
    FONG, GH
    ROSSANT, J
    GERTSENSTEIN, M
    BREITMAN, ML
    [J]. NATURE, 1995, 376 (6535) : 66 - 70
  • [79] INDUCTION OF HUMAN VASCULAR ENDOTHELIAL STRESS FIBERS BY FLUID SHEAR-STRESS
    FRANKE, RP
    GRAFE, M
    SCHNITTLER, H
    SEIFFGE, D
    MITTERMAYER, C
    DRENCKHAHN, D
    [J]. NATURE, 1984, 307 (5952) : 648 - 649
  • [80] TUMOR-NECROSIS-FACTOR TYPE-ALPHA, A POTENT INHIBITOR OF ENDOTHELIAL-CELL GROWTH-INVITRO, IS ANGIOGENIC INVIVO
    FRATERSCHRODER, M
    RISAU, W
    HALLMANN, R
    GAUTSCHI, P
    BOHLEN, P
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (15) : 5277 - 5281